Recruiting studies: Cd19 Positive Relapsed Or Refractory B Cell Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT06834529 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518 A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528 Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461 CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
NA · 1 location(s) · Hong Kong Children's Hospital · NCT06866873 UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT06092047 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07133997 Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06213636 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/Phase 2 · 9 location(s) · Vironexis Biotherapeutics Inc. · NCT06533579 Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Phase 1 · 1 location(s) · Seoul National University Hospital · NCT05210907 Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Maligna
Phase 1 · 1 location(s) · Nelson Hamerschlak · NCT05705570 Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Phase 1 · 1 location(s) · Beijing Yongtai Ruike Biotechnology Company Ltd · NCT06047197 SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT06544265

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.